Objective The purpose of this study was to determine the prevalence and prognostic significance of exercise-induced ventricular arrhythmias (EIVAs) in patients referred for exercise testing, considering the arrhythmic substrate and exerciseinduced ischemia.
Conclusions
Exercise induced ischemia does not affect the prognostic value of EIVAs, whereas the arrhythmic substrate does. EIVAs and resting PVCs are both independent predictors of mortality after consideration of other clinical and exercise-test variables. These findings are of limited clinical significance because of the modest change in risk and the lack of any established intervention. However, they explain some of the previous controversy and highlight the need to consider resting PVCs and follow-up duration in assessing the clinical implications of EIVAs. (Am Heart J 2003;145: 139-46.) Recent exercise testing consensus documents confirm that exercise testing is an important prognostic tool. Low exercise capacity and exercise-induced cardiac ischemia were reported to be the strongest predictors of mortality.
1 Ventricular arrhythmias can be induced by exercise testing 2 ; however, at present, the prognostic significance of exercise-induced ventricular arrhythmias (EIVAs) remains unclear. Previous research studying the prognostic significance of EIVAs in those investigated for cardiac disease offers conflicting results. Some studies suggest that EIVAs confer a poor prognosis [3] [4] [5] while others demonstrate that EIVAs are benign. [6] [7] [8] The clinical significance of EIVAs in those without documented cardiovascular disease presents another prognostic dilemma. Although a recent study found that healthy volunteers with EIVAs had increased mortality, 9 earlier studies did not produce similar results. 10, 11 It is unclear whether the prognosis associated with EIVAs differs based on the presence of cardiovascular disease, ischemic changes during exercise, and presence of premature ventricular contractions at rest (ie, an indicator of the arrhythmic substrate).
In order to further elucidate the prognostic significance of EIVAs, we analyzed the association of EIVAs with mortality in our database of Ͼ6000 male veterans referred for exercise tests. We assessed the risk associated with EIVAs on the basis of patient demographics, medical history, resting electrocardiogram (ECG) find-ings, and exercise test results after a mean period of follow up of 6 years.
Methods

Population
The population consisted of 6213 consecutive male patients referred to 2 clinical exercise laboratories (Long Beach VA 1987-1991, Palo Alto VA 1992-2000) directed in a consistent fashion by 2 of the authors (VF and JM). Patients who were subjects in research protocols were not considered in the analyses.
Data collection
Both labs had affiliations with Universities and had academic medical staffs with rotating house officers and fellows. All tests were supervised directly by these individuals or by nurse practitioners; all tests were over-read by 2 of the investigators (VF and JM). A thorough clinical history, listing of medications, and risk factors were recorded prospectively at the time of the exercise tests by use of computerized forms beginning in 1987. 12, 13 The forms included standard definitions of clinical conditions and exercise responses. No imaging modality was performed in conjunction with the tests.
Exercise testing
Patients underwent treadmill testing that used progressive protocols with small but frequent incremental steps. [14] [15] [16] Tests were symptom-limited except for those stopped according to the criteria listed in the guidelines. 1 Medications were not changed or stopped before testing. Patients were encouraged to use the handrails only if necessary for balance. Heart rate targets were not used as an end point or to judge the adequacy of the test. Patients did not perform a cool down walk but were placed supine as soon as possible postexercise. 17 After careful skin preparation, a standard 12 lead ECG was obtained before and continuously during exercise and for at least 5 minutes into recovery. ST-segment depression was measured visually at the J junction; ST slope was measured over the following 60 ms and classified as upsloping, horizontal, or downsloping. The ST-segment response considered was the most horizontal or downsloping ST-segment depression in any lead except aVR during exercise or recovery. An abnormal response was defined as Ն1 mm of horizontal or downsloping ST-segment depression. Exercise ischemia was coded when angina and/or abnormal ST depression occurred. The commercially available recorders used, Mortara X-scribe (Milwaukee, Wis) and Burdick Quest (Madison, Wis), had arrhythmia sensing that provided tracings automatically and manually, as well as freeze/playback capabilities. EIVAs were considered to be present if frequent premature ventricular contractions (PVCs), constituting Ͼ10% of all ventricular depolarizations during any 30-second ECG recording, or ventricular tachycardia, a run of Ն3 consecutive PVCs, were visually detected by test supervisors during the exercise test or recovery. Resting PVCs were considered present if any PVC was detected in the 10-second supine ECG before exercise. When PVCs appeared at rest, in order for EIVAs to be considered present, PVCs had to become frequent with exercise.
Blood pressure was taken manually and METs (metabolic equivalents) were estimated from treadmill speed and grade. 18 No test was classified as indeterminate. 19 Normal standards for age-predicted exercise capacity were derived from regression equations published previously among veterans referred for exercise testing 20 : we defined patients with cardiovascular and/or pulmonary disease as those with a history of angiographically-documented coronary artery disease, myocardial infarction, coronary bypass surgery, coronary angioplasty, congestive heart failure, peripheral vascular disease, or an abnormal exercise test response suggesting coronary artery disease (Ն1.0 mm ST-segment depression, exercise-induced angina, or both). Seven percent of the population also had a history of mild pulmonary disease defined as diagnosed obstructive disease not requiring medications or obviously limiting exercise; these subjects were included in the diseased group (n ϭ 3679). All others were classified as normal (n ϭ 2534).
Follow-up
The Social Security Death Index was used to match all of the patients by use of name and social security number. The index is updated weekly and current information was used. Death status was determined as of July 2000 and was complete. Unfortunately, we do not have cause of death or other follow-up information on our patients.
Statistical analysis
Number Crunching System Software (Salt Lake City, Utah) was used for all statistical analyses after transferring the data from an ACCESS (Microsoft, Redmond, Wash) database. Demographics, medical history, and clinical and exercise test findings were compared between those with and without EIVAs. The t test and 2 analysis were used to compare variables univariately. Survival analysis was performed by use of Kaplan Meier curves to compare variables and cut-points, and log rank tests were used to assess whether statistically significant differences in survival were present. Total (all-cause) mortality was used as the end point for survival analysis. Censoring was not performed because data regarding subsequent interventions were not available for all patients. The age-adjusted hazard ratios for EIVAs along with the 95% CIs were calculated from a Cox proportional hazards model adjusted for age.
A Cox proportional hazards model was used to determine which variables were independently and significantly associated with time to death. Hazard ratios were calculated along with their 95% CIs. Risk factors that were entered into the Cox model to predict mortality included age, presence of cardiovascular and pulmonary disease (with the exception of exercise-induced ischemia), history of hypertension, diabetes, current smoking habit, resting tachycardia, resting PVCs, resting ST-segment depression, ECG left ventricular hypertrophy with ST depression (strain), poor exercise capacity (Ͻ5 METs), maximum heart rate Ͻ85% of age-predicted value (chronotropic incompetence), exercise-induced ST depression and/or angina and EIVAs.
Results
Prevalence
Of the 6213 male veterans included in the study, none had frequent PVCs at rest. Patient demographics and the prevalence of cardiovascular comorbidities, and clinical and exercise test findings are described in Table I . EIVAs were present in 503 patients (8%). Patients with EIVAs were older and were more likely to have cardiovascular and/or pulmonary disease, resting PVCs, and exercise-induced ischemia (exercise test induced abnormal ST depression and/or angina) compared with those without EIVAs. Among patients with 
Survival
The average annual all-cause mortality was 3.2% (mean follow-up 6 Ϯ 4 years). The average annual mortality in those with EIVAs (4.6%) was significantly greater than for those without EIVAs (3.0%) (P Ͻ .001). The log rank test for determining statistically significant differences in survival demonstrated that, in those with PVCs at rest, survival was similar between those with and without suppression of PVCs with exercise (P ϭ .665). A Kaplan Meier survival curve was constructed for those with and without EIVAs according to the presence or absence of cardiovascular and/or pulmonary disease (Figure 1) . The Log rank test found that EIVAs predicted mortality in those with (P Ͻ .001) and without disease (P ϭ .025). In the group without disease, the univariate hazard ratio indicated that there was no increased mortality associated with EIVAs at 4-years follow up (1.13 [95% CI 0.66-1.95]); however, at 8-years follow up, EIVAs were a significant predictor of mortality (1.97 [95% CI 1.27-3.04]).
In order to assess the prognostic utility of EIVAs in relation to other clinical findings, Kaplan Meier curves were constructed for those with and without EIVAs in association with the presence or absence of ischemia during exercise (exercise induced angina and/or STsegment depression) (Figure 2 ). Log rank tests demonstrated that EIVAs predicted mortality in those with (P Ͻ .001) and without (P ϭ .002) ischemia during exercise testing. Figure 3 Kaplan-Meier curve demonstrating survival in those with or without EIVAs (EIVA) in association with the presence or absence of cardiovascular or pulmonary disease (CV-P). EIVAs predict mortality in those with and those without cardiovascular or pulmonary disease. Asterisk, P ϭ .025; double asterisks, P Ͻ .001.
Figure 2
Kaplan-Meier curve demonstrating survival in those with or without EIVAs (EIVA) in association with the presence or absence of myocardial ischemia during exercise. EIVAs predict mortality in those with or without exercise-induced myocardial ischemia. Asterisk, P ϭ .002; double asterisks, P Ͻ .001.
Figure 3
Kaplan-Meier curve demonstrating survival in those with or without EIVAs (EIVA) in association with the presence or absence of PVCs at rest. EIVAs predict mortality in those without PVCs at rest, but were not predictive of mortality in those with PVCs at rest. rank tests demonstrated that although EIVAs were predictive in those without resting PVCs (P Ͻ .001), EIVAs did not predict mortality in those with resting PVCs (P ϭ .495).
After adjusting for age, hazard ratios associated with EIVAs demonstrated that EIVAs did not predict mortality in those without cardiovascular and/or pulmonary disease (P ϭ .241) and with resting PVCs (P ϭ .766) (Table II) .
Because prognosis was similar for patients with resting PVCs and those with resting PVCs that became frequent with exercise, these 2 groups were combined into 1 resting PVC group. Demographics, medical history, clinical findings, and exercise test findings were then compared among 3 groups: those with no ventricular ectopy at rest or during exercise, those with EIVAs only, and those with resting PVCs with or without EIVAs. As shown in Table III , those without any ventricular ectopy were younger and had a lower prevalence of cardiovascular or pulmonary disease and exercise-induced ischemia than the other 2 groups. Resting heart rate was greater in those with resting PVCs compared with those with EIVAs only (P Ͻ .001), and the prevalence of exercise-induced ischemia (P ϭ .027) was greatest in those with EIVAs only.
In the Cox hazard multivariate analysis shown in Table IV, both EIVAs and resting PVCs were independent predictors of mortality after considering age, clinical, resting, and exercise test variables. Aside from age, poor exercise capacity (Ͻ5 METs) and cardiovascular and pulmonary disease were the strongest predictors of mortality. Exercise-induced ischemia was not found to be an independent predictor of mortality when clinical and other exercise test variables were considered.
Discussion
Previous studies
EIVAs are common during exercise testing, and although researched extensively, their clinical significance remains poorly defined. Previous studies consistently suggest that the prevalence of EIVAs increases in older populations 2, 5, 6 and in those with cardiovascular disease. 2, 4, 21 Some studies suggest that EIVAs may result from exercise-induced ischemia, because the prevalence of EIVAs increases in those with ischemia 5, 22 ; however, other studies refute these results. 6, 8, 10, 23, 24 The prognostic significance of EIVAs has also generated controversy. Some studies have shown that EIVAs are not strong predictors of mortality after recovery from myocardial infarction 8, 24 and in patients with coronary artery disease (CAD). In a small study by Nair et al, 25 frequent or complex exercise-induced PVCs did not predict 4-year mortality in patients with CAD. Sami et al 7 and Weiner et al 22 also reported that patients who experienced at least 1 PVC during exercise were not at increased risk of mortality during a 5-year follow-up period. More recently, Schweikert et al 6 found that in patients with CAD with no history of severe ventricular ectopy at rest, exercise-induced frequent or complex PVCs were not predictive of 2-year mortality. Other studies of patients with known or suspected heart disease demonstrate that PVCs during exercise are associated with increased mortality. [3] [4] [5] In asymptomatic individuals, studies of those without known heart disease found no association between EIVAs and mortality 10, 11 ; however, Jouven et al 9 recently reported that asymptomatic males with frequent exercise-induced PVCs had a 2.5-times greater risk of long-term mortality than males without EIVAs.
Inconsistency in study design is largely responsible for the discrepancies in these previous studies. Many earlier studies used small sample sizes and short follow-up periods. Sex of the study population most likely also affected the results. The Framingham study reported that while asymptomatic males with frequent or complex PVCs on ambulatory ECG were at increased risk of mortality, asymptomatic females were not. 26 This study and findings by Jouven et al 9 found EIVAs to be predictive of mortality when male populations were considered. Previous studies have used varying criteria to define EIVAs, with some studies considering EIVAs to be present if any PVC was recorded during exercise. The prevalence of EIVAs will be more reproducible on future exercise tests if frequent or complex PVCs are used as markers for EIVAs instead of occasional PVCs. 24 In addition, others have documented an increased risk of mortality in those with frequent or complex PVCs during exercise compared with those with only occasional PVCs. 3, 9 Finally, there is inconsistency in previous reports regarding the inclusion or exclusion of those with resting PVCs.
This study tried to address these limitations. A large sample size was used with a relatively long follow-up. The prognostic significance of EIVAs was compared between those with and without cardiovascular disease by use of the same methodology. Unlike many previous studies, ours took into consideration the presence of exercise-induced ischemia and resting PVCs when determining the prognostic utility of EIVAs.
Cardiovascular disease
We confirmed that the prevalence of EIVAs increased in those who have cardiovascular and/or pulmonary disease. By use of the log rank statistic, EIVAs were found to be predictive of mortality in those with and without disease. Although EIVAs were not a marker of mortality in those without disease after adjusting for age, in a univariate analysis, we found that the risk associated with EIVAs was nonsignificant early in follow up but became significant near the end of follow up. In the study by Jouven et al, 9 EIVAs were long-term predictors of mortality in a healthy population. From these findings we hypothesize that the arrhythmic substrate responsible for EIVAs may pose no immediate risk for mortality, but individuals could become more susceptible to its effects with age. Aging is associated with loss of vagal tone 27 and other processes that can result in myocardial fibrosis and ischemia, potentially lowering the threshold to arrhythmias later in life in those who are initially free of cardiovascular disease.
Exercise-induced ischemia
We found that ischemia (ST depression and/or angina) was associated with EIVAs because ischemia was more prevalent in the "EIVAs only" subgroup compared with those with resting PVCs with or without EIVAs and those with neither rest nor exercise ventricular ectopy. The presence of EIVAs added greater pre- dictive power to the finding of exercise-induced ischemia alone.
Resting PVCs
Our findings indicate that resting PVCs were associated with the development of EIVAs. Although resting PVCs are associated with EIVAs, they do not seem to contribute additional prognostic information to the finding of resting PVCs alone. Further studies investigating EIVAs should differentiate those with resting PVCs from those without resting PVCs because this marker of the arrhythmic substrate impacts on the prevalence and prognostic significance of EIVAs.
Limitations
Our findings are limited in that they are applicable only to men, which could be important due to possible sex differences in the prognostic significance of PVCs. In addition, we only had all-cause mortality data; we did not have specific cause of death nor were we able to censor on cardiovascular interventions. In the study by Jouven et al, 9 EIVAs predicted mortality when both all-cause mortality and cardiovascular mortality were used as end points. Our "apparently healthy" group had no history of cardiovascular or pulmonary disease and had a normal exercise test response, but all of the patients in this group were referred for exercise testing within the Veterans Affairs health care system. 28 However, echocardiograms might have detected cardiac disease in a portion of them either initially or during follow up.
Further limitations relate to our a priori determined coding of PVCs. Although this is a strength for hypothesis testing, we were unable to go back and recode our data. In fact, this strengthens our findings and supports further work in this area by now most assuredly considering resting PVCs. Our data were coded in terms of whether EIVAs were occasional or frequent in nature, but we did not precisely quantify the PVC rate at rest or during exercise, and therefore we could not determine the rate of increase with exercise. We did not code exercise PVCs as appearing solely during recovery and we did not code PVC morphology. Further investigations should examine how the morphology of EIVAs affects prognosis and, for those with PVCs at rest, whether the rate of increase of PVCs with exercise further influences mortality.
Finally, the increase in mortality associated with PVCs that we found was modest (slightly Ͼ1% annually) and there is no established therapy, making our findings of limited clinical significance.
Conclusion
Because EIVAs are associated with an increased risk for death, health professionals should encourage men with EIVAs, particularly those with known cardiopulmonary disease, to receive regular health maintenance, comply with established therapies, and to aggressively modify risk factors. Patients without cardiopulmonary disease should be reassured that EIVAs present no immediate risk but be reevaluated after 5 years. 
